Explanatory video by ASCERTAIN: Maureen Rutten-van Mölken explains what referencepricing means and how comparing medicine prices across countries can affect both affordability and access.
Watch the first video: https://lnkd.in/eHisrn8x
The EU funded project ASCERTAIN (Affordability and Sustainability improvements through new pricing, Cost- Effectiveness and ReimbursemenT models to Appraise INnovative health technologies) addresses the need of patients, physicians, payers, regulators, and manufacturers to improve the affordability and accessibility to innovative health technologies (including pharmaceuticals) in Europe.
ASCERTAIN – IMPROVING ACCESS TO INNOVATIVE HEALTH TECHNOLOGIES